2. Outline of seminar
At the end of the session the students will be able to
ā¢ Define pancreatitis
ā¢ State the types of pancreatitis
ā¢ List the causes
ā¢ Explain the pathophysiology
ā¢ Identify the clinical manifestations
ā¢ List the diagnostic investigations
ā¢ Describe the management
ā¢ Discuss the nursing management
ā¢ List the complications
ā¢ State the prognosis
10/4/2023
Neelima
Shakya
2
3. Anatomy of pancreas
ā¢ Structure-12-15 ā cm long J-
shaped, soft, lobulated,
retroperitoneal organ.
ā¢ Location-lies transversely behind
the stomach, at (L1-2) spine.
ā¢ The head of the pancreas lies in
the duodenal C loop in front of
the inferior vena cava constitutes
about 50% of the total pancreas
ā¢ The body and tail of the pancreas
run obliquely upward to the left
in front of the aorta and left
kidney
10/4/2023
Neelima
Shakya
3
4. Functions of pancreas
Exocrine
ā¢ 1.5ā3 L of alkaline (pH >
8.0) fluid/day containing
about 20 enzymes under
stimulation of secretin and
cholecystokinin
ā¢ joins the common bile duct
to form the
hepatopancreatic ampulla
controlled by the
hepatopancreatic sphincter
(of Oddi).
ā¢ Constitute 80% of
pancreatic parenchyma
Endocrine
ā¢ Scattered throughout the
gland containing beta cells
(secrete insulin), alpha cells
(secrete glucagon), delta
cells (secrete somatostatin)
ā¢ constitute only about 2% of
the pancreatic
parenchyma.
10/4/2023
Neelima
Shakya
4
6. AUTOPROTECTIONOFTHE PANCREAS
ā¢ Autodigestion of the pancreas is prevented by packaging
of proteases in precursor form and by the synthesis of
protease inhibitors, i.e., pancreatic secretory trypsin
inhibitor (PSTI) and serine protease inhibitor found in
the acinar cell.
ā¢ low calcium concentrations within the pancreas also
decrease trypsin activity.
ā¢ After reaching to duodenum trypsinogen converts to
trypsin by enterokinase which facilitates conversion of
other proenzymes.
ā¢ Loss of any of these protective mechanisms leads to
zymogen activation, autodigestion, and acute
pancreatitis.
10/4/2023
Neelima
Shakya
6
8. Acute pancreatitis
ā¢ Acute nonbacterial inflammatory condition of
the pancreas, derived from the early activation
of digestive enzymes with variable compromise
of the gland itself, nearby tissues and other
organs and generally resolves over time.
ā¢ Range from mild discomfort to a severe, life-
threatening illness.
10/4/2023
Neelima
Shakya
8
9. Epidemiology
ā¢ Worldwide, the incidence ranges between 5 and
80 per 100,000 population
ā¢ In Finland and USA the main cause of AP is alcohol,
whereas studies from Hong Kong, England, Italy,
and Greece showed biliary AP to be more
common.
10/4/2023
Neelima
Shakya
9
10. Common causes of pancreatitis
ā¢ Biliary disease- 40%
ā¢ Alcohol intake more than 5-15 years or
binge drinking- 35%
ā¢ ERCP- 4%
ā¢ Trauma
ā¢ Drugs- azathioprine, valproic acid,
methyldopa, estrogen
ā¢ Hyperlipidemia- triglyceride >1000 mg/dl
ā¢ Scorpion bite
10/4/2023
Neelima
Shakya
10
11. Uncommon Causes
ā¢ Bacterial, viral, fungal and parasitic infection
ā¢ Vascular causes and vasculitis
ā¢ Cancer of the pancreas
ā¢ Hypercalcemia
ā¢ Cystic fibrosis
ā¢ Renal failure
ā¢ Postoperative (abdominal and nonabdominal operations)
10/4/2023
Neelima
Shakya
11
12. Etiology
GET SMASHED
G - Gall stones, most common
E ā Ethanol, second most common
T ā Trauma
S ā Steroids
M ā Mumps
A āAutoimmune Pancreatitis
S ā Scorpion sting
Hāhyperlipidaemia triglyceride >11.3 mmol/L(>1000
mg/dL).Hypothermia, Hyperparathyroidism
E - Endoscopic retrograde cholangiopancreatography
D - Drugs - azathioprine, valproic acid, methyldopa, estrogen.
10/4/2023
Neelima
Shakya
12
13. Pathophysiology
ā¢ Pancreatic enzymes are present in acinar cells in the proenzyme
form and have to be activated to fulfill their enzymatic potential.
ā¢ Trypsin has a major role in the autodigestion
ā¢ Once trypsin is generated, it activate other proenzymes such as
prophospholipase and proelastase, which then take part in the
process of autodigestion.
ā¢ The activated enzymes cause disintegration of fat cells and
damage the elastic fibers of blood vessels.
ā¢ Trypsin also converts prekallikrein to kinin system cause
inflammation and small-vessel thromboses.
ā¢ Macrophase activation- local inflammatory response
ā¢ Increased vascular permability
ā¢ Excreted into circulation causing systemic complications
10/4/2023
Neelima
Shakya
13
15. Clinical features
ā¢ Abdominal pain- Constant, midepigastric
or periumbilical, radiating to the back or
flank. Patient assumes a fetal position or
leans forward while sitting to relieve
pressure of the inflamed pancreas on
celiac plexus nerves.
ā¢ Nausea and vomiting.
ā¢ Fever.
ā¢ Involuntary abdominal guarding,
epigastric tenderness to deep palpation
10/4/2023
Neelima
Shakya
15
16. Contd..
ā¢ Dry mucous membranes; hypotension; cold,
clammy skin; cyanosis; and tachycardia
ā¢ Korte's sign: pain in the zone where the head
of pancreas is located (in epigastrium, 6ā7 cm
above the umbilicus)
ā¢ Jaundice due to compression of common bile
duct.
10/4/2023
Neelima
Shakya
16
17. ā¢ Erythematous skin nodules due to subcutaneous
fat necrosis.
ā¢ Pulmonary findings -rales, atelectasis, and pleural
effusion most frequently left-sided.
ā¢ Bowel sounds are usually diminished or absent.
ā¢ An enlarged pancreas with organized necrosis or a
pseudocyst may be palpable in the upper
abdomen.
10/4/2023
Neelima
Shakya
17
18. Contdā¦
ā¢ Turner's sign -Purplish discoloration
of the flanks indicate
retroperitoneal hemorrhage
ā¢ Cullen's sign - Purplish discoloration
of periumbilical area
ā¢ occurs in extensive hemorrhagic
necrosis of the pancreas as the
result of hemoperitoneum
10/4/2023
Neelima
Shakya
18
19. Diagnostic investigations
ā¢ History- History should be taken regarding
alcohol , Gall stone , abdominal pain, vomiting
etc.
ā¢ Physical examination- Cullenās sign, Turnerās
sign, hypotension, cold, clammy skin, cyanosis,
dehydration and tachycardia.
10/4/2023
Neelima
Shakya
19
20. Blood test
Blood amylase or lipase- lipase a better indicator
Amylase
ā¢ More than four times normal (normal 25-100 IU/L)
ā¢ Rises within 2 - 3 hr, peaks at 12 - 24 hr and returns to normal after
3 - 5 days
Lipase
ā¢ Increase within 4 - 8 hr, peak at 24 hr to > 2 times the upper limit
of normaland may remain elevated for 10 - 14 days.
Plasma C-reactive protein -āgold-standardā in predicting the
severity of acute pancreatitis, as a peak level of > 210 mg/L (on
the second, third or fourth day), or a level > 120 mg/L at the
end of the first week
10/4/2023
Neelima
Shakya
20
21. Contdā¦
ā¢ The plasma procalcitonin level- predictor of a
pancreatic infection.
ā¢ ABG-hypoxia, and lactic acidosis in severe
ā¢ Hyperglycemia
ā¢ Hypocalcemia
ā¢ LFT-Hyperbilirubinemia, return to normal in 4ā7 days.
ā¢ serum lactic dehydrogenase (LDH) levels - >500 U/L
(normal <200)
10/4/2023
Neelima
Shakya
21
22. Contdā¦
ā¢ Abdominal ultrasound- to detect gallstones, alcoholic fatty liver
ā¢ ECG-ST segment and T-wave abnormalities
ā¢ CT Scan/MRI of abdomen- CECT -to identify inflammation of the
pancreas, fluid collection and any changes in the density of the
gland.
ā¢ ERCP to determine the exact location of a gallstone.
ā¢ Abdominal X-ray- To detect an ileus or isolated loop of small bowel
overlying pancreas.
ā¢ Chest X-ray- collapsed lung tissue, pleural effusion.
10/4/2023
Neelima
Shakya
22
23. Classification of acute pancreatitis
This classification defines three degrees of severity:
mild acute pancreatitis, moderately severe acute
pancreatitis, and severe acute pancreatitis.
10/4/2023
Neelima
Shakya
23
24. Contdā¦
Mild acute pancreatitis
ā¢ No organ failure
ā¢ No local or systemic complications
Moderately severe acute pancreatitis
ā¢ Organ failure that resolves within 48 h (transient organ failure)
ā¢ Local or systemic complications
Severe acute pancreatitis
ā¢ Persistent organ failure (>48 h)
ā¢ Single or multiple organ failure
ā¢ one or more local complications.
10/4/2023
Neelima
Shakya
24
26. DIAGNOSTIC CRITERIA
Several scoring systems are used to predict the severity of an attack of
pancreatitis.
According to Ransonās criteria
1. Age >55 years
2. WBC >16,000 mm3
3. Serum glucose >200 mg/dL (>11.1 mmol/L)
4. Serum LDH >350 IU/L (>350 U/L)
5. AST >250 U/mL (120 U/L)
6. Fall in hematocrit >10% (>0.10)
7. BUN increase >5 mg/dL (>1.7 mmol/L)
8. Serum calcium <8 mg/dL (<2.0 mmo/L)
9. Base deficit >4 mEq/L (>4 mmol/L)
10. Fluid retention or sequestration >6 L
11. PO2<60 mm Hg
ā¢ Total Score= 11
10/4/2023
Neelima
Shakya
26
27. Ransoncriteriaforpredictingtheseverityof
acutepancreatitis
At admission
1. Age in years > 55 years
2. white blood cell count >
16000 cells/mm3
3. Blood glucose >
10 mmol/L (> 200 mg/dL)
4. serum AST > 250 IU/L
5. serum LDH > 350 IU/L
The presence of 3 or more
criteria indicates severe
pancreatitis
At 48 hours
1. Calcium (serum calcium <
2.0 mmol/L (< 8.0 mg/dL)
2. Hematocrit fall >10 %
3. Oxygen (hypoxemia PO2 <
60 mmHg)
4. BUN >5 mg/dL after IV fluid
hydration
5. -Base deficit (negative base
excess) > 4 mEq/L
6. Sequestration of fluids > 6 L
The presence of 3 or more
criteria indicates severe
pancreatitis
10/4/2023
Neelima
Shakya
27
29. Management
ā¢ self-limited in 85ā90% and subsides spontaneously,
usually within 3ā7 days after treatment is
instituted.
ā¢ No definite treatment
10/4/2023
Neelima
Shakya
29
30. General approach
Fluid resuscitation
ā¢ NPO
ā¢ intravenous fluid-250-500 ml/hour (RL preferred)
Pain management
ā¢ Morphine avoided as it cause spasm of the sphincter of oddi;
paracetamol, tramadol, pethidine used.
ā¢ If gallstones- cholecystectomy during the same hospital
admission.
ā¢ Antiemetic.
10/4/2023
Neelima
Shakya
30
31. Nutritional support
ā¢ Feeding enterally- NG, FJ
ā¢ low-fat and low protein diet initially.
ā¢ In mild uncomplicated pancreatitis oral feedings once the
patientās pain and anorexia resolve.
ā¢ Total parenteral nutrition when calorie requirement not
met by enteral nutrition
Antibiotics
ā¢ Routine prophylactic antibiotics not recommended
ā¢ Infected necrosis who fail to improve after 7 ā 10 days
antibiotics E.g.- carbapenems, quinolones, and
metronidazole
10/4/2023
Neelima
Shakya
31
32. ā¢ Patients with severe acute pancreatitis
require intensive care.
ā¢ discharged when their pain is well controlled
with oral analgesia, able to tolerate an oral
diet and all complications have been
addressed adequately
10/4/2023
Neelima
Shakya
32
33. Surgical Intervention if complications
occur
ā¢ In patients with gallstones- cholecystectomy
ā¢ If necrotizing biliary AP, cholecystectomy deferred until
active inflammation subsides
ā¢ In stable patients with infected necrosis, surgical,
radiologic, and endoscopic drainage should be delayed
preferably for more than 4 weeks to allow liquefication
of the contents and the development of a fibrous wall
around the necrosis.
ā¢
10/4/2023
Neelima
Shakya
33
35. Endoscopic Pancreatic Sphincterotomy
ā¢ to reduce pancreatic duct pressure and to
facilitate other procedures such as pancreatic
stent placement, tissue sampling, dilation of
strictures, or stone removal.
10/4/2023
Neelima
Shakya
35
36. Roux-en-Y Choledochojejunostomy
ā¢ The choledochojejunostomy is indicated in patients who
have recurrent stones, intrahepatic stones, or distal
biliary strictures.
10/4/2023
Neelima
Shakya
36
37. The Puestow Procedure
ā¢ An 8ā10-cm segment of the pancreatic duct is unroofed and
intraductal concretions removed . The jejunum is divided and
the opened pancreatic duct is anastomosed to the jejunum.
10/4/2023
Neelima
Shakya
37
38. Prevention
ā¢ Avoiding heavy alcohol use will help to prevent
pancreatitis.
ā¢ Prevent gallstones may help to prevent gallstone-
related acute pancreatitis.
ā¢ If the cause is gallstones, gallbladder surgery will
usually be recommended to prevent future attacks.
ā¢ When a medication is the likely cause, it will be
stopped if possible.
10/4/2023
Neelima
Shakya
38
39. Prognosis
ā¢ Overall mortality in patients with acute pancreatitis
is 10-15%. Patients with biliary pancreatitis tend to
have a higher mortality than patients with alcoholic
pancreatitis.
ā¢ In patients with severe disease (organ failure), who
account for about 20% of presentations, mortality is
approximately 30%.
ā¢ In patients with necrosis without organ failure,
mortality approaches zero.
10/4/2023
Neelima
Shakya
39
41. Chronic pancreatitis
ā¢ Continuing, chronic, inflammatory process of the
pancreas, characterized by irreversible
morphologic changes
ā¢ Presence of histologic abnormalities, including
chronic inflammation, fibrosis, and progressive
destruction of both exocrine and eventually
endocrine tissue.
10/4/2023
Neelima
Shakya
41
42. Epidemiology
ā¢ The worldwide prevalence 4-5%
ā¢ The incidence of CP ranges from 1.6 to 23 cases per
100,000 per year worldwide.
ā¢ It affects 10-15 per 100,000 population in Western
countries but is much higher in Japan - 45 per 100,000.
ā¢ male:female ratio 4:1 and a median patient age of 51
10/4/2023
Neelima
Shakya
42
44. Clinical features
ā¢ The abdominal pain radiating to the back,
both upper and lower quadrants.
ā¢ Eating may exacerbate the pain
ā¢ Epigastric tenderness
ā¢ Sitting up and leaning forward relieve.
ā¢ Maldigestion - chronic diarrhea (>6/ day),
steatorrhea, weight loss, and fatigue.
ā¢ Diabetes mellitus.
10/4/2023
Neelima
Shakya
44
45. Diagnostic evaluation
ā¢ Serum amylase and lipase may be normal to low because
of decreased pancreatic exocrine function.
ā¢ Fecal fat analysis
ā¢ Bilirubin and alkaline phosphatase may be elevated
ā¢ Secretin and cholecystokinin stimulatory test results
abnormal
ā¢ Plain abdominal X-ray to determine diffuse calcification of
the pancreas.
ā¢ CT scan for calcifications, masses, ductal irregularities,
enlargement, and pseudocysts.
ā¢ ERCP defines ductal anatomy and localizes complications,
such as pancreatic pseudocysts and ductal disruptions.
10/4/2023
Neelima
Shakya
45
46. Management
ā¢ Avoidance of alcohol
ā¢ Enzyme therapy to control diarrhoea and restores absorption
of fat.
ā¢ Tricyclic antidepressants to decrease pain and potentiate the
effects of opiates. Eg: Amitriptyline hydrochloride
ā¢ Octreotide subcutaneous injection 3 times daily at 200mcg
ā¢ high-protein, high-calorie diets.
10/4/2023
Neelima
Shakya
46
47. ā¢ In severely malnourished chronic pancreatitis
patients, total parenteral nutrition
ā¢ Diabetes mellitus treated with diet, insulin, or
oral antidiabetic agents.
ā¢ Endoscopic treatment -sphincterotomy, stenting,
stone extraction, and drainage of a pancreatic
pseudocyst.
ā¢ Surgery and autologous islet cell transplantation
10/4/2023
Neelima
Shakya
47
48. Surgical management
ā¢ The puostow procedure
ā¢ Whipple procedure-Standard
pancreaticoduodenectomy involves
resection of the head of the
pancreas, duodenum, gallbladder,
distal common bile duct and antrum.
ā¢ Distal pancreatectomy
ā¢ Celiac nerve block- The celiac plexus
is located on the anterolateral
surface of the aorta at the T12āL2
spinal level.
10/4/2023
Neelima
Shakya
48
49. Nursing Assessment
ā¢ abdominal pain
ā¢ nutritional status
ā¢ steatorrhea and malabsorption
ā¢ signs and symptoms of diabetes mellitus
ā¢ current alcohol intake and motivation and
resources available to abstain from
drinking
ā¢ Obtain history of gallbladder disease
ā¢ respiratory rate and pattern and breath
sounds.
10/4/2023
Neelima
Shakya
49
50. Nursing Diagnoses
ā¢ Acute and chronic pain related to acute/ chronic and
unrelenting insult to pancreas
ā¢ Imbalanced nutrition: less than body requirements related
to fear of eating, malabsorption, and glucose intolerance
ā¢ Deficient Fluid Volume related to vomiting, self-restricted
intake, fever, and fluid shifts
ā¢ Ineffective Breathing Pattern related to severe pain and
pulmonary complications
ā¢ Impaired skin integrity related to poor nutritional status,
bed rest, and multiple drains and surgical wound
ā¢ Anxiety related to surgical intervention
10/4/2023
Neelima
Shakya
50
51. Controlling pain
ā¢ Assess character, location, frequency, duration, precipitating
and alleviating factors of pain.
ā¢ Nonpharmacologic methods- distraction, imagery, and
progressive muscle relaxation.
ā¢ Administer opioid analgesics.
ā¢ Assist patient to a comfortable position.
ā¢ Maintain NPO status to decrease pancreatic enzyme
secretion.
ā¢ Maintain patency of NG suction.
ā¢ frequent oral hygiene and care.
ā¢ Administer antacids or H2-receptor antagonists.
ā¢ Report increase in severity of pain, which may indicate
hemorrhage, rupture of a pseudocyst, or inadequate dosage
of the analgesic.
10/4/2023
Neelima
Shakya
51
52. Improving respiratory function
ā¢ Assess respiratory rate and rhythm, effort,
oxygen saturation, and breath sounds
frequently.
ā¢ upright or semi-Fowler's position
ā¢ oxygen supplementation
ā¢ Report signs of respiratory distress
immediately.
ā¢ coughing and deep breathing
ā¢
10/4/2023
Neelima
Shakya
52
53. Improving nutrition
ā¢ Assess nutritional status, weight loss,
dietary habits, alcohol intake.
ā¢ Administer pancreatic enzyme
replacement with meals.
ā¢ Administer antacids or h2-receptor
antagonists
ā¢ Monitor intake and output and daily
weight.
ā¢ Low-fat diet.
10/4/2023
Neelima
Shakya
53
54. Maintaining adequate fluid volume
ā¢ Monitor and record vital signs, skin color, and
temperature, intake/output, weight daily.
ā¢ Evaluate laboratory data for hemoglobin,
hematocrit, albumin, calcium, potassium, sodium,
and magnesium levels and administer replacements
as prescribed.
ā¢ Observe and measure abdominal girth if pancreatic
ascites is suspected.
ā¢ Report trends in falling blood pressure or urine
output or rising pulse, which indicate hypovolemia
and shock or renal failure.
10/4/2023
Neelima
Shakya
54
55. Improving skin integrity
ā¢Turn the patient every 2 hours.
ā¢Apply moisturizers
ā¢Provide skin care
ā¢Bedmaking as necessary
10/4/2023
Neelima
Shakya
55
56. Relieving anxiety
ā¢ Describe patient for surgery as well as adverse
effects and complications of surgery.
ā¢ Total pancreatectomy - permanent diabetes
mellitus, dependence on insulin, severe
malabsorption, and the need for lifelong
pancreatic enzyme replacement.
ā¢ encouraging abstinence of alcohol and intake of
nutritional and vitamin supplements.
ā¢ After surgery, provide meticulous care to prevent
infection, promote wound healing, and prevent
routine complications of surgery.
10/4/2023
Neelima
Shakya
56
57. Patient education
ā¢ gradually resume a low-fat diet.
ā¢ Instruct patient to increase activity gradually
ā¢ Reinforce information about disease process and
precipitating factors.
ā¢ eliminate all alcohol
ā¢ Instruct in proper administration of pancreatic enzyme
replacement.
ā¢ Take just before or during meals.
ā¢ Take with antacid or take H2-receptor antagonist as
directed to prevent pancreatic enzyme from being
destroyed by gastric acid secretions
10/4/2023
Neelima
Shakya
57